As the former diagnostics division of Wako Chemicals USA, Wako Life Sciences will capitalize on its decades long reputation for high quality diagnostic reagents branded as Wako Diagnostic products. The new streamlined organization will accelerate the development of microfluidic test systems for the immunoassay and molecular diagnostic markets.

The successful use of novel microfluidics technology was first introduced with the flagship IVD test system, μTASWako® i30, launched in 2011 for the liver cancer market. "Creating medical diagnostic value through innovative technology is the core of Wako Life Sciences", said President, Dr. Shinji Satomura. "We will leverage our research and development of microfluidic-based test systems to provide in vitro diagnostic products with rapid "sample to answer" turnaround, and superior assay sensitivity and specificity".

Wako Life Sciences, Inc. is headquartered in Mountain View, CA and has R&D facilities and commercial operations in Mountain View and Richmond, VA. Wako Life Sciences, Inc. is a wholly owned subsidiary of Wako Pure Chemical Industries, Ltd.